Insight Genetics: Meeting the Need for Advanced ALK Diagnostics
Insight Genetics is meeting the need for advanced ALK diagnostics.
Read More
Search Results for: lung cancer
Published Data Highlights CDK Inhibitor’s Potential Against Breast Cancer
Targeting CDK2/cyclin E with Cyclacel’s CYC065 reportedly overcomes Herceptin resistance in HER2-positive breast cancer.
Read More
News Story #15302
Positive Early Results for Parkinson’s Treatment Michael J. Fox Harbor BioSciences, San Diego, which is investigating the use the company’s proprietary compound Triolex as a treatment for Parkinson’s disease (PD) with fund
Read More
Getting Personal
Personalized medicine, one goal of molecular diagnostics that is already being clinically realized, offers the opportunity to treat individuals with greater efficacy and efficiency than ever before.
Read More
Insight Genetics, St Jude Children’s Research Hospital Enter Licensing Agreement
Insight Genetics has licensed rights for mutations in the anaplastic lymphoma kinase (ALK) gene that confer resistance to ALK inhibitors.
Read More